Anticoagulants remain one of the top three drug classes responsible for avoidable adverse drug events. Knowledge surrounding these medications, as well as skills for application, are paramount for optimal safe and effective management plans, particularly when applied to special populations and controversial settings. This session will explore several thrombosis-related clinical controversies the pharmacist clinician can relate to. Attendees  will learn how to pursue the best course of treatment in these contentious conundrums. Four 15-minute segments will be presented by expert panelists, focused on developing audience skills to deal with clinical controversies in antithrombotic management where there may be limited or flawed data to guide judgment. A 30-minute, case-based discussion will follow the four 15-minute segments where all four panelists will provide diverse perspectives on the application of the information to presented cases to solidify learning and allow for audience interaction. The sessions will cover topics in acute care (Alteplase vs. Tenecteplase for acute ischemic stroke, antiplatelet bridging, liver disease, and obesity) as well as ambulatory care (duration of dual antiplatelet therapy, use of genetic testing, combination anticoagulation and antiplatelet therapy), and special populations (antiphospholipid syndrome, CKD/IHD, transcatheter aortic valve replacement).  

Faculty

Moderator: Sarah Hanigan Lewis, Pharm.D., BCCP, BCPS Title: Antiplatelets, Anticoagulants, and Adverse Effects, Oh My! Antithrombotic Therapy Controversies in Clinical Practice Institution: University of Michigan College of Pharmacy City/State: Northville, MI   View Biography